title: Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652.
abstract: A low cation conductance and a high anion conductance are characteristic of normal erythrocytes. In sickle cell anemia, the polymerization of hemoglobin S (HbS) under conditions of low oxygen tension is preceded by an increase in cation conductance. This increase in conductance is mediated in part through Ca(++)-activated K(+) channels. A net efflux of potassium chloride (KCl) leads to a decrease in intracellular volume, which in turn increases the rate of HbS polymerization. Treatments minimizing the passive transport of ions and solvent to prevent such volume depletion might include inhibitors targeting either the Ca(++)-activated K(+) channel or the anion conductance. NS1652 is an anion conductance inhibitor that has recently been developed. In vitro application of this compound lowers the net KCl loss from deoxygenated sickle cells from about 12 mmol/L cells/h to about 4 mmol/L cells/h, a value similar to that observed in oxygenated cells. Experiments performed in mice demonstrate that NS1652 is well tolerated and decreases red cell anion conductance in vivo. (Blood. 2000;95:1842-1848)
authors.affiliation: August Krogh Institute, University of Copenhagen, Denmark. pbennekou@aki.ku.dk
authors.forename: P
authors.initials: P
authors.lastname: Bennekou
authors.forename: O
authors.initials: O
authors.lastname: Pedersen
authors.forename: A
authors.initials: A
authors.lastname: Møller
authors.forename: P
authors.initials: P
authors.lastname: Christophersen
mesh_terms: D000755:Anemia, Sickle Cell / Q000473:pathology*; D000818:Animals; D000838:Anions / Q000097:blood*; D001565:Benzoates / Q000494:pharmacology* / Q000633:toxicity; D001704:Biopolymers; D048429:Cell Size / Q000187:drug effects; D018118:Chloride Channels / Q000097:blood / Q000187:drug effects*; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane / Q000187:drug effects*; D004913:Erythrocytes, Abnormal / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D006451:Hemoglobin, Sickle / Q000737:chemistry / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D007739:L Cells / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010671:Phenylurea Compounds / Q000494:pharmacology* / Q000633:toxicity; D015221:Potassium Channels / Q000097:blood*; D011189:Potassium Chloride / Q000097:blood; D013431:Sulfates / Q000097:blood
chemical_list: D000838:Anions; D001565:Benzoates; D001704:Biopolymers; D018118:Chloride Channels; D006451:Hemoglobin, Sickle; D006454:Hemoglobins; D010671:Phenylurea Compounds; D015221:Potassium Channels; D013431:Sulfates; D011189:Potassium Chloride; C100003:deoxyhemoglobin; C405615:NS 1652